Diarrhea News and Research

Latest Diarrhea News and Research

Soligenix initiates orBec Phase 2 study for GI manifestations of chronic GVHD

Soligenix, Inc., a clinical stage biopharmaceutical company focused on developing products to treat serious inflammatory diseases where there remains an unmet medical need, as well as developing several biodefense vaccines and therapeutics, announced today that it has initiated a Phase 2, randomized, double-blind, placebo-controlled study evaluating orBec (oral beclomethasone 17,21-dipropionate or BDP) as a treatment for the gastrointestinal manifestations of chronic Graft-versus-Host disease.

2 Dec 2013

Children of PTSD afflicted mothers are at high risk of developing this disorder

A Ben-Gurion University of the Negev (BGU) study indicates that children are more likely to develop Post Traumatic Stress Disorder (PTSD) if their mother is already afflicted.

27 Nov 2013

Restoring helpful bacteria of the gut and intestines may treat patients with RCDI, find scientists

Scientists at the Institute for Genome Sciences at the University of Maryland School of Medicine and physicians at Sinai Hospital, Baltimore, MD, have found that restoring the normal, helpful bacteria of the gut and intestines may treat patients suffering from recurrent Clostridium difficile infections. Transplanting fecal matter of healthy donors into patients with recurrent C. difficile infection appears to restore normal bacterial composition and resolve infection.

27 Nov 2013

Merck announces approval of NOXAFIL delayed-release tablets by FDA

Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved NOXAFIL® (posaconazole) 100 mg delayed-release tablets.

27 Nov 2013

CHMP adopts positive opinion for ABRAXANE with gemcitabine for treatment of metastatic pancreas

Celgene International Sàrl, a wholly-owned subsidiary of Celgene Corporation, today announced that the European Medicines Agency's: Committee for Medicinal Products for Human Use has adopted a positive opinion for ABRAXANE (paclitaxel formulated as albumin bound nanoparticles, or nab-paclitaxel) in combination with gemcitabine for first-line treatment of adult patients with metastatic adenocarcinoma of the pancreas.

25 Nov 2013

NEXAVAR tablets receive FDA approval for treatment of patients with thyroid cancer

Bayer HealthCare and Onyx Pharmaceuticals, Inc., an Amgen subsidiary, today announced that the U.S. Food and Drug Administration has approved a supplemental New Drug Application for the oral multi-kinase inhibitor NEXAVAR (sorafenib) tablets for the treatment of patients with locally recurrent or metastatic, progressive, differentiated thyroid carcinoma refractory to radioactive iodine treatment.

23 Nov 2013

Vaccinating kids against rotavirus may also reduce risk of seizures

A new study suggests an additional-and somewhat surprising-potential benefit of vaccinating children against rotavirus, a common cause of diarrhea and vomiting. Besides protecting kids from intestinal illness caused by rotavirus, immunization may also reduce the risk of related seizures, according to findings published in Clinical Infectious Diseases and available online.

21 Nov 2013

FDA accepts Merck's NOXAFIL IV solution NDA for priority review

Merck, known as MSD outside the United States and Canada, today announced that its New Drug Application for an investigational intravenous solution formulation of the company's antifungal agent, NOXAFIL (posaconazole), has been accepted for priority review by the U.S. Food and Drug Administration.

18 Nov 2013

Gilead Sciences gets marketing authorization from European Commission for Vitekta tablets

Gilead Sciences, Inc. today announced that the European Commission has granted marketing authorization for Vitekta (elvitegravir 85 mg and 150 mg) tablets, an integrase inhibitor for the treatment of HIV-1 infection in adults without known mutations associated with resistance to elvitegravir.

18 Nov 2013

Zafgen presents safety, efficacy data from beloranib Phase 2 study at Obesity Week 2013

Zafgen, Inc., a leading biopharmaceutical company dedicated to addressing the unmet needs of severely obese patients, today announced final efficacy and safety data from its recently completed Phase 2 study of beloranib, a selective inhibitor of methionine aminopeptidase 2.

15 Nov 2013

European Commission grants marketing authorization for Bayer HealthCare's Xofigo injection

Bayer HealthCare announced today that the European Commission has granted marketing authorization for Xofigo (radium Ra 223 dichloride) solution for injection for the treatment of adults with castration-resistant prostate cancer, symptomatic bone metastases and no known visceral metastases. This decision follows a positive recommendation from the European Committee for Medicinal Products for Human Use in September of this year.

15 Nov 2013

Imbruvica gets FDA approval for treatment of mantle cell lymphoma

The U.S. Food and Drug Administration today approved Imbruvica (ibrutinib) to treat patients with mantle cell lymphoma, a rare and aggressive type of blood cancer.

13 Nov 2013

Synergy Pharmaceuticals starts first phase 3 clinical trial of plecanatide in CIC patients

Synergy Pharmaceuticals Inc. today announced the start of the first of two planned phase 3 clinical trials to confirm the safety and efficacy of plecanatide, its lead GC-C agonist and once-daily oral treatment, in adult patients with chronic idiopathic constipation.

13 Nov 2013

Results announced for Phase 3B/4 study of RAPAMUNE in kidney transplant patients

Pfizer Inc. (NYSE:PFE) announced today top-line results from a Phase 3B/4 study of RAPAMUNE® (sirolimus) evaluating kidney transplant patients who transitioned from tacrolimus-based therapy (TAC) to RAPAMUNE® 3 to 5 months after transplant.

12 Nov 2013

First generic versions of Aciphex delayed-release tablets get FDA approval for GERD treatment

The U.S. Food and Drug Administration today approved the first generic versions of Aciphex (rabeprazole sodium) delayed-release tablets, used to treat gastroesophageal reflux disease in adults and adolescents (ages 12 and up).

10 Nov 2013

Cumberland Pharmaceuticals net revenue decreases from $12.5 to $6.5 million

Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company focused on hospital acute care and gastroenterology, today announced third quarter 2013 financial results.

5 Nov 2013

Experimental drug effective in treating patients with non-small cell lung cancer

An experimental cancer drug that has shown promise in the treatment of melanoma has also shown early potential as an effective treatment for patients with non-small cell lung cancer, the leading cause of cancer death among men and women worldwide.

4 Nov 2013

Toxicity limits benefits of bevacizumab–erlotinib NSCLC maintenance therapy

Two targeted anticancer drugs used together after first-line chemotherapy for advanced stage non-small-cell lung cancer improve progression-free survival, the results of a large, prospective study show.

31 Oct 2013

Interim data from Phase 1B trial of an investigational anti-PD-1 immunotherapy in patients with previously-treated NSCLC announced by Merck

Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced the presentation of interim data from a Phase 1B trial (PN001) evaluating MK-3475, an investigational anti-PD-1 immunotherapy, in patients with previously-treated non-small cell lung cancer (NSCLC). The data were presented today by Dr. Edward Garon, Director of Thoracic Oncology, Jonsson Comprehensive Cancer Center, University of California, Los Angeles, at the 15th World Conference on Lung Cancer in Sydney, Australia (Abstract #2416).

31 Oct 2013

Viropharma announces financial results for third quarter 2013

ViroPharma Incorporated reported today its financial results for the third quarter ended September 30, 2013. Net sales were $113 million for the third quarter ended September 30, 2013, as compared to $91 million in the same three months of 2012.

31 Oct 2013

Diarrhea News and Research

Latest Diarrhea News and Research

Soligenix initiates orBec Phase 2 study for GI manifestations of chronic GVHD

Children of PTSD afflicted mothers are at high risk of developing this disorder

Restoring helpful bacteria of the gut and intestines may treat patients with RCDI, find scientists

Merck announces approval of NOXAFIL delayed-release tablets by FDA

CHMP adopts positive opinion for ABRAXANE with gemcitabine for treatment of metastatic pancreas

NEXAVAR tablets receive FDA approval for treatment of patients with thyroid cancer

Vaccinating kids against rotavirus may also reduce risk of seizures

FDA accepts Merck's NOXAFIL IV solution NDA for priority review

Gilead Sciences gets marketing authorization from European Commission for Vitekta tablets

Zafgen presents safety, efficacy data from beloranib Phase 2 study at Obesity Week 2013

European Commission grants marketing authorization for Bayer HealthCare's Xofigo injection

Imbruvica gets FDA approval for treatment of mantle cell lymphoma

Synergy Pharmaceuticals starts first phase 3 clinical trial of plecanatide in CIC patients

Results announced for Phase 3B/4 study of RAPAMUNE in kidney transplant patients

First generic versions of Aciphex delayed-release tablets get FDA approval for GERD treatment

Cumberland Pharmaceuticals net revenue decreases from $12.5 to $6.5 million

Experimental drug effective in treating patients with non-small cell lung cancer

Toxicity limits benefits of bevacizumab–erlotinib NSCLC maintenance therapy

Interim data from Phase 1B trial of an investigational anti-PD-1 immunotherapy in patients with previously-treated NSCLC announced by Merck

Viropharma announces financial results for third quarter 2013

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Diarrhea News and Research

Latest Diarrhea News and Research

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in